What is permexa™ sodium caprate, and what problem does it solve for oral peptide medicines?

Permexa™ sodium caprate is a newly launched intestinal permeation enhancer developed by Ashland to facilitate the oral delivery of peptides, biologics, and low-permeability drugs—including GLP-1 agonists. It addresses key formulation challenges such as inconsistency, lack of process robustness, and scalability limitations in oral drug product development, combining the established functionality of sodium caprate with enhanced pharmaceutical processing performance.

Why is Ashland's launch of permexa™ sodium caprate significant for the pharmaceutical industry?

The launch is significant because it responds to strong global interest and positive feedback from pharmaceutical companies, biotech firms, and contract development and manufacturing organizations (CDMOs), reflecting growing demand for advanced excipients that enable reliable oral delivery of complex biologics—particularly as oral GLP-1 therapies gain clinical and commercial traction. It also marks an expansion of Ashland’s portfolio dedicated specifically to oral biologics delivery.

Ashland Launches New Ingredient for Oral Peptide Medicines

Aug 24, 2026

Ashland has launched permexa™ sodium caprate, an intestinal permeation enhancer designed to facilitate the oral delivery of peptides and biologics such as GLP-1 agonists. This excipient aims to improve formulation consistency and scalability for pharmaceutical processing.

Stock Titan

2026-04-01

Ashland Inc Stock: Specialty Chemicals Leader Faces Evolving Industrial Demands in 2026

2026-04-04

Allspring Global Investments Reduces Stake in Ashland Inc. to $25.69 Million

2026-04-06

Ashland Raises Prices Across Product Lines Amid Cost Pressures

2026-04-11

Ashland Inc. (NYSE:ASH) Given Consensus Rating of "Hold" by Analysts

2026-04-13

Massachusetts Financial Services Co. Lowers Stock Position in Ashland Inc.